Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- In obesity, growing CV risk burden demands cross-specialty collaboration, new solutions
-
- In congenital heart surgery, success is much more than ratings Daniel A. Velez, MD
- FDA panel unanimously supports CV event risk reduction indication for icosapent ethyl
- HF after STEMI more common in women vs. men
- Insomnia increases CVD risk
- LEGEND-HTN: Thiazide, thiazide-like diuretics superior to ACE inhibitors
- Racial disparities in emergent HF care, outcomes identified
- AMBER: Patiromer enables persistent spironolactone treatment in patients with hypertension, CKD
- Benefit of nonculprit PCI for STEMI consistent regardless of timing: COMPLETE
-
- COLCOT: Low-dose colchicine reduces CV risk after MI
- Dapagliflozin confers consistent benefit in HF without diabetes: DAPA-HF
- Evening eating may worsen heart health in women
- GALILEO: Rivaroxaban raises death, thrombotic, bleeding risk vs. antiplatelet therapy after TAVR
- Genetic testing may identify patients at risk for sudden cardiac death
- Icosapent ethyl shows benefit on several plaque characteristics at 9 months: EVAPORATE
- ISCHEMIA: Invasive strategy, medical therapy yield similar CV outcomes in stable ischemia
- Portico valve stacks up against commercially available TAVR valves
-
- REMEDIAL III: Hydration guided by urine flow rate cuts contrast-induced acute kidney injury
- Role of wearable devices increasing in health care
- Sacubitril/valsartan beneficial in real-world HFrEF population
- Statin intolerance can be fought with intermittent dosing
- EVAPORATE
- FIND-FH
- FUEL
- GALILEO
-
- ISCHEMIA
- LEGEND-HTN
- MARVEL-2
- ORION-10